

**Institutional Biosafety  
Committee Minutes  
September 11, 2025  
Zoom Meeting 1:30 pm**

**Members Present**

Bertram Jacobs  
Al Jensen  
Drew Solomon  
Christopher Plaisier  
Mitch Magee  
Matthew Scotch  
Valerie Stout  
Giorgio Scarpellini  
Hugh Mason  
Kathleen Kennedy  
Yixin Shi

**Affiliated Participants**

Greg Powell  
Sarah Hurd  
Stephanie Durst-Real  
Karen Stevenson  
Amanda Rice  
Mary Turlington-Powell

**Institutional Official**

Debra Murphy

**Visitors Present**

Yu Ping Poh  
Mark Wang  
Joseph Roberts  
Anne Nelson

**Supporting Participants**

Bree Prinzhorn  
Kristy Macdonald  
Nicole Shepherd

Note: This meeting was conducted via Zoom. Meeting Format: Open meeting

**Call to Order:** The IBC Chair called the meeting to order at 1:30 pm and a quorum was confirmed. Introductions were made.

**Minutes**

The meeting minutes from August 14, 2025, were reviewed by the committee. A motion was made to approve the minutes as presented. The motion was seconded.

Total Vote: 11      Approved: 10      Opposed: 0      Abstained: 1      Recused: 0

**Conflicts of Interest**

The IBC Chair called for conflicts. No conflicts were reported.

**Disclosures for Committee Review:**

**Wideman SPROTO2025-58 (BSL2 Renewal)**

**Wideman 2025**

**Primary Reviewer: Matthew Scotch**

The lab manager provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on the cellular nature of non-pathogenic microbial eukaryotes. Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-E, III-F-1, and III-F-8, Appendices C-II and C-III. A motion was made to approve the disclosure as presented. The motion was seconded.

Total Vote: 11      Approved: 11      Opposed: 0      Abstained: 0      Recused: 0

**Roberts SPROTO2025-66 (BSL2 Renewal)**

**Roberts Microbiota, Pain, and Metabolism**

**Primary Reviewer: Hugh Mason**

The PI provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on intestinal microbiota, fracture-induced pain, and post-traumatic metabolism.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-E, III-E-3, III-E-3-a, III-F-1, and III-F-8, Appendices C-I and C-VII. A motion was made to approve the disclosure as presented. The motion was seconded.

Total Vote: 11

Approved: 11

Opposed: 0

Abstained: 0

Recused: 0

**Wang, Mark SPROTO2025-64 (BSL2 Renewal)**

**Wang – Vascular Inflammation Therapeutics**

**Primary Reviewer: Chris Plaisier**

The PI provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on cardiovascular disease and various approaches to atherosclerosis. The following changes were administratively made to the disclosure:

- Checked section III-D-4-a on the NIH Guidelines page.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-D, III-D-1, III-D-1-a, III-D-4, III-D-4-a, III-E, III-E-1, III-F-1, and III-F-8, Appendices C-I, C-II, and C-VII. A motion was made to approve the disclosure as modified. The motion was seconded.

Total Vote: 11

Approved: 11

Opposed: 0

Abstained: 0

Recused: 0

**Additional Business:**

**Consent Agenda**

The committee reviewed and acknowledged the consent agenda.

**1. Biosafety Officer's Report**

- The Biosafety Officer informed the committee of regular PAPR checks. No degradation has been found and no PAPR's are close to the usage limit.
- The Biosafety Officer informed the committee of an amendment that will require full committee review at the next IBC meeting.
- The committee reviewed and discussed recent NIH announcements.
- The committee reviewed and discussed a Gain of Function memo released by the Office of General Counsel.
- The committee discussed potential modifications to the current BSL3 training program. PI's are interested in continuing to use the mentor approach. The Biosafety Team will work with various PI's on modifications to the training program and return to the IBC for guidance.

2. **Education Item:** Reticular thalamic hyperexcitability drives autism spectrum disorder behaviors in the Cntnap2 model of autism

The meeting was adjourned at 2:47 pm. The next IBC Meeting will be held on October 9, 2025 at 1:30 pm.